Click here for slides on this topic


Fasting plasma glucose (FPG)

Glucose concentration in plasma obtained after an 8- to 10-hour overnight fast. A fasting plasma glucose (FPG) level <100 mg/dL is considered normal; 101-125 mg/dL, indicates impaired glucose tolerance (IGT); ≥126 mg/dL, frank diabetes if the level is reproducible and not found during an acute illness.
The following content matched the glossary term: Fasting plasma glucose (FPG)

AACE 2015 guidelines Glycemic Targets

Top

Summary of glycemic treatment targets, including the A1C goal, from the 2015 AACE diabetes guidelines 

AACE 2015 guidelines Diabetes Diagnosis

Top

Summary of recommendations for screening and diagnosing type 2 diabetes from the 2015 AACE guidelines. 

HARMONY 3: 104-week trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride

Top

Ahrén B, Johnson SL, Stewart M, et al; for the HARMONY 3 Study Group. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care. 2014;37(8):2141-2148.

ADA 2016 Children & Adolescents

Top

Recommendations for treating and managing diabetes in children from the 2016 ADA guidelines

ADA 2016 Diabetes Screening and Diagnosis

Top

Criteria for type 2 diabetes diagnosis from the 2016ADA guidelines

European Association for the Study of Diabetes (EASD) 49th Annual Meeting 2013 - Bile-Acid Sequestrants Offer Dual-Action Benefit in Type 2 Diabetes

Top

NDEI's coverage of the European Association for the Study of Diabetes (EASD) 49th Annual Meeting 2013 from Barcelona, Spain

 

European Association for the Study of Diabetes (EASD) 49th Annual Meeting 2013

Top

NDEI's coverage of the European Association for the Study of Diabetes (EASD) 49th Annual Meeting 2013 from Barcelona, Spain

Clinical Insights in Diabetes Newsletter July 2013

Top

Clinical Insights® in Diabetes newsletter July 2013

Carotid intima-media thickness (CIMT) change in ORIGIN-GRACE, effects of omega-3 fatty acids on CV events in the Risk and Prevention Study, canagliflozin therapy in CANTATA-D2 and CANTATA-M, weight gain and intensive therapy in ACCORD, glycemic control with single daily basal insulin plus corrective glulisine and basal bolus regimen, diurnal pattern to insulin action in type 1 diabetes.

AAP 2013 Guidelines - Type 2 Diabetes in Children and Adolescents

Top

Guidelines for managing type 2 diabetes in children and adolescents from the American Academy of Pediatrics (AAP) 2013

1 2 3 4 5 6 7 8 9 10  ... Next 

Slide Library Results

Search Results for: Fasting plasma glucose (FPG) Slides Found: 34
Type 2 Diabetes in US Adults: Overview
Vildagliptin Monotherapy Improves Glycemic Control in Type 2 Diabetes
Changing Glucose: Different Rates at Different Clinical Stages
UKPDS: Progressive Deterioration in Glycemic Control Over Time
Fasting Plasma Glucose and the Acute Insulin Response
Sitagliptin Improves Glycemic Control in Patients With Type 2 Diabetes Not Controlled With Pioglitazone
ADOPT: Cumulative Incidence of Monotherapy Failure at 5 Years
ADOPT: Achievement of A1C Levels <7%
Vildagliptin: Change in Mean A1C During 24-Week Treatment
Sitagliptin Reduces FPG in Patients With Type 2 Diabetes Not Controlled With Metformin
Sitagliptin Monotherapy Reduces FPG in Patients With Type 2 Diabetes
Effect of Sitagliptin Monotherapy on A1C in Patients With Type 2 Diabetes
Sitagliptin Reduces FPG in Patients With Type 2 Diabetes Not Controlled With Pioglitazone
Effects of Sitagliptin vs Glipizide on FPG in Patients With Type 2 Diabetes Not Controlled With Metformin
Effect of Exenatide + TZD on Blood Glucose in Patients With Type 2 Diabetes
Effect of Sitagliptin + Metformin on FPG in Patients with Type 2 Diabetes
RECORD: Effect of Rosiglitazone or Metformin Add-on to Sulfonylurea on A1C and FPG
RECORD: Effect of Rosiglitazone or Sulfonylurea Add-on to Metformin on A1C and FPG
Effect of Sitagliptin vs Rosiglitazone When Added to Metformin Monotherapy
ACCORD-MIND: Relationship Between Glycemia Status, CVD, Stroke, Smoking Status, and Cognitive Test Scores
Odds Ratios of In-Hospital Mortality by Admission and Fasting Glucose Levels
Mortality Risk Up to 6-Months in Patients With or Without Diabetes
Prevalence of IFG, IGT, and Prediabetes by Cardiometabolic Risk Factors
Prevalence of IFG, IGT, and Prediabetes According to a Combination of Central Obesity and Hyperinsulinemia
Efficacy of Pioglitazone Plus Sibutramine in Metformin-Intolerant vs Metformin-Tolerant Obese Subjects With Type 2 Diabetes
Impact of Higher Heart Rate on Development of Cardiometabolic Risk Factors After 20 Years
Saxagliptin for Treatment of Type 2 Diabetes: Mean Change in FPG from Baseline to Week 24
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Design
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Change in A1C from Baseline to Week 52
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Additional Results
STAMPEDE Results: Primary Endpoint (A1C ≤6%) at 12 Months
CANTATA-D2: Significantly Greater FPG Reduction with Canagliflozin Vs Sitagliptin at 52 Weeks
CANTATA-M: Significant FPG Reductions with Canagliflozin vs Placebo at 26 Weeks
AACE 2015 Diabetes Guidelines Prediabetes Diagnosis IFG IGT PPT | NDEI